Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Interleukin-4 - DNAX; Quadrakine; SCH 39400

Latest Information Update: 20 Aug 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Nonindustrial sources; Schering-Plough
  • Class Interleukins
  • Mechanism of Action B cell stimulants; Interleukin 1 beta inhibitors; Interleukin 4 receptor agonists; Interleukin 6 receptor antagonists; Interleukin 8 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal cancer; Immunodeficiency disorders; Inflammation; Kaposi's sarcoma; Malignant melanoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 20 Aug 2009 Discontinued - Clinical-Phase-Unknown for Psoriasis in Netherlands (SC)
  • 26 May 2003 Clinical trials in Psoriasis in Germany (SC)
  • 26 May 2003 Clinical trials in Psoriasis in Netherlands (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top